ABBV STOCK HITS RECORD ALL TIME HIGH

Quote




















anonymous said:
This is being looked at very closely and related to Citron's "dirty money" accusation.
Big surprise on ER coming Friday. Another cat will be let out of the bag.
Click to expand...


Surprise Surprise Surprise ER beat Street and Stock tanks almost 4.36% (so far)
Short this dog. The Longs are Catching the Falling Knife. Lucky i dumped @ $115

AbbVie Inc
NYSE: ABBV
$89.84 USD DOWN−$4.10 (4.36%)
Jul 27, 9:52 AM
 




anonymous said:
Surprise Surprise Surprise ER beat Street and Stock tanks almost 4.36% (so far)
Short this dog. The Longs are Catching the Falling Knife. Lucky i dumped @ $115

AbbVie Inc
NYSE: ABBV
$89.84 USD DOWN−$4.10 (4.36%)
Jul 27, 9:52 AM
Click to expand...

Ricky is addressing the Citron attack right now on conference call Also he is discussing the ip system, patent disputes, & settlements. This guy is sweating bullets right now !!!!!!
 




anonymous said:
Ricky is addressing the Citron attack right now on conference call Also he is discussing the ip system, patent disputes, & settlements. This guy is sweating bullets right now !!!!!!
Click to expand...

Heres to you Ricky
....................../'¯/)
....................,/¯../
.................../..../
............./´¯/'...'/´¯¯`·¸
........../'/.../..../......./¨¯\
........('(...´...´.... ¯~/'...')
.........\.................'...../
..........\............... _.·´
............\..............(
..............\.............\
 








The reason stocks tanking after beating ER is because of several reasons
1. Cintron
2. FDA
3. Humira revenue figure was boosted by foreign exchange. Humira's sales increased 8.2% from the prior-year period but y/y growth was subpar compared to historical performance.
4. HCV/Mavyret' nice looking @ $973 million BUT Mavyret's momentum is slowing and market share decreasing.
5. Rova T
6. Ricks an IDIOT
 




anonymous said:
The reason stocks tanking after beating ER is because of several reasons
1. Cintron
2. FDA
3. Humira revenue figure was boosted by foreign exchange. Humira's sales increased 8.2% from the prior-year period but y/y growth was subpar compared to historical performance.
4. HCV/Mavyret' nice looking @ $973 million BUT Mavyret's momentum is slowing and market share decreasing.
5. Rova T
6. Ricks an IDIOT
Click to expand...

and CEO succession pipeline questionable.
 












Humira sales down in Q2 with Mylan and Amgen ready to pounce on market share.
Fast track approval for Rova T turns into no approval.
Citron attaches a price target of $60.
Fda fast tracking generics to breech Humira patent proctection.
Metrics on whole pipeline tanking.
ROA for 2017 at lowest levels since 2014, returning 7.5% compared to a high of 9.7% in 2015. Working capital for 2017 saw its lowest level of 1.28. Now ROA for 2018 is looking even worse.

ALL this and Rick raises guidance?
 












anonymous said:
Humira sales down in Q2 with Mylan and Amgen ready to pounce on market share.
Fast track approval for Rova T turns into no approval.
Citron attaches a price target of $60.
Fda fast tracking generics to breech Humira patent proctection.
Metrics on whole pipeline tanking.
ROA for 2017 at lowest levels since 2014, returning 7.5% compared to a high of 9.7% in 2015. Working capital for 2017 saw its lowest level of 1.28. Now ROA for 2018 is looking even worse.

ALL this and Rick raises guidance?
Click to expand...

Since January the stock has fallen a whopping 28%. YIKES !!!
 




I am resigned to the fact that our company's leadership won't be resigning all at once. So, given that fact and the fact that that the pipeline never fails to disappoint, what needs to happen for this company to succeed in a 3-5 year post-Humira timeframe? It seems to me that we need to begin cutting costs now, lay off a lot of people, and shrink this company quickly to what we think will be its post-Humira size. What do you think? What AbbVie leaders can take us where we need to go?
 












Top Bottom
Back
Quote